A request was made for regulatory guidance on approving pharmaceutical cocrystals—crystalline forms combining an active drug and coformers in defined ratios. Cocrystals enhance drug bioavailability, stability, and manufacturability, especially for APIs without ionizable groups. Applicants must prove their superior properties over physical mixtures using advanced diffraction and spectroscopic methods. If confirmed as cocrystals, products are treated as new drugs requiring manufacturing validation, stability, and clinical studies, following the New Drugs and Clinical Trials Rules, 2019.
A representation has been received seeking clarification on the regulatory pathway for the approval of pharmaceutical cocrystals. Cocrystals are crystalline materials composed of an active pharmaceutical ingredient (API) and coformers in a defined stoichiometric ratio, bonded nonionically and noncovalently.
They offer advantages over conventional solid forms, such as improved bioavailability, stability, and manufacturability, especially for APIs lacking ionizable groups needed for salt formation.
To be classified as pharmaceutical cocrystals, applicants must demonstrate superior physicochemical or pharmacokinetic properties compared to physical mixtures of the same components, confirmed through diffraction and spectroscopic analyses.
If not meeting these criteria, the product is treated as a fixed-dose combination. Cocrystals of approved active substances are considered new drugs, requiring validation of manufacturing, stability, and clinical studies.
Such applications must comply with the New Drugs and Clinical Trials Rules, 2019, and be submitted accordingly.